Syncromune is a clinical-stage biopharmaceutical company developing novel intratumoral immunotherapies for solid tumors. The company is developing Syncrovax, a proprietary platform technology that uses a combination approach to synchronize the timing and location of tumor antigen release with the functional activation of immune cells. Syncromune's mission is to optimize intratumoral, immuno-oncology drug development, and to bring life-changing therapies to cancer patients in need. It was founded in 2020 and is based in Fort Lauderdale, Florida.
Partial Data by Infogroup (c) 2024. All rights reserved.